Exagen Inc (XGN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.83 is considered Undervalued compared with the five-year average of -5.25. The fair price of Exagen Inc (XGN) is between 24.71 to 29.24 according to relative valuation method. Compared to the current price of 3.55 USD , Exagen Inc By Undervalued By 85.63%.

Relative Value

Fair Zone

24.71-29.24

Current Price：3.55

85.63%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Exagen Inc (XGN) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Exagen Inc (XGN) has a current Price-to-Book (P/B) ratio of 7.50. Compared to its 3-year average P/B ratio of 5.05, the current P/B ratio is approximately 48.54% higher. Relative to its 5-year average P/B ratio of 3.71, the current P/B ratio is about 102.00% higher. Exagen Inc (XGN) has a Forward Free Cash Flow (FCF) yield of approximately -8.03%. Compared to its 3-year average FCF yield of -39.90%, the current FCF yield is approximately -79.88% lower. Relative to its 5-year average FCF yield of -36.83%, the current FCF yield is about -78.19% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for XGN competitors is 53.68, providing a benchmark for relative valuation. Exagen Inc Corp (XGN.O) exhibits a P/S ratio of 1.83, which is -96.59% above the industry average. Given its robust revenue growth of 37.87%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of XGN increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of XGN in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is XGN currently overvalued or undervalued?

What is Exagen Inc (XGN) fair value?

XGN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Exagen Inc (XGN) is between 24.71 to 29.24 according to relative valuation method.

How does XGN's valuation metrics compare to the industry average?

The average P/S ratio for XGN's competitors is 53.68, providing a benchmark for relative valuation. Exagen Inc Corp (XGN) exhibits a P/S ratio of 1.83, which is -96.59% above the industry average. Given its robust revenue growth of 37.87%, this premium appears sustainable.

What is the current P/B ratio for Exagen Inc (XGN) as of Mar 03 2026?

As of Mar 03 2026, Exagen Inc (XGN) has a P/B ratio of 7.50. This indicates that the market values XGN at 7.50 times its book value.

What is the current FCF Yield for Exagen Inc (XGN) as of Mar 03 2026?

As of Mar 03 2026, Exagen Inc (XGN) has a FCF Yield of -8.03%. This means that for every dollar of Exagen Inc's market capitalization, the company generates -8.03 cents in free cash flow.

What is the current Forward P/E ratio for Exagen Inc (XGN) as of Mar 03 2026?

As of Mar 03 2026, Exagen Inc (XGN) has a Forward P/E ratio of -10.39. This means the market is willing to pay $-10.39 for every dollar of Exagen Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Exagen Inc (XGN) as of Mar 03 2026?

As of Mar 03 2026, Exagen Inc (XGN) has a Forward P/S ratio of 1.83. This means the market is valuing XGN at $1.83 for every dollar of expected revenue over the next 12 months.

XGN Valuation